Compass Therapeutics (CMPX) Projected to Post Earnings on Thursday

Compass Therapeutics (NASDAQ:CMPX) is anticipated to release its earnings data before the market opens on Thursday, March 20th. Analysts expect Compass Therapeutics to post earnings of ($0.10) per share for the quarter.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.01). On average, analysts expect Compass Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compass Therapeutics Trading Down 1.7 %

CMPX stock opened at $2.31 on Wednesday. The stock has a 50-day moving average price of $2.84 and a two-hundred day moving average price of $2.06. The stock has a market cap of $319.43 million, a PE ratio of -6.24 and a beta of 1.19. Compass Therapeutics has a 1 year low of $0.77 and a 1 year high of $4.08.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on CMPX shares. Jefferies Financial Group increased their target price on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Piper Sandler started coverage on Compass Therapeutics in a report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 target price for the company. HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a report on Wednesday, January 8th. D. Boral Capital reiterated a “buy” rating and set a $32.00 target price on shares of Compass Therapeutics in a report on Tuesday, February 25th. Finally, Guggenheim began coverage on Compass Therapeutics in a report on Monday, February 24th. They set a “buy” rating and a $12.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Compass Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $11.38.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.